molecules-logo

Journal Browser

Journal Browser

Effect of Natural Products in the Cancer Therapy Mechanism—2nd Edition

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: 30 May 2026 | Viewed by 785

Special Issue Editor


E-Mail Website
Guest Editor
Department of Physiology in Health Sciences, Faculty of Health Sciences, Pomeranian Medical University, Szczecin, Poland
Interests: cancer metastasis; pathophysiology; molecular biology; gene polymorphism; epigenetic drugs; epigenetics; physiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Natural products and, in particular, plant-derived molecules, have long been a cornerstone of drug discovery and remain one of the richest sources of anticancer agents. Numerous plant-derived compounds, including vincristine, vinblastine, paclitaxel, docetaxel, etoposide, and camptothecin derivatives, are established in clinical oncology and continue to inspire new generations of therapeutic agents. These molecules often target fundamental cellular pathways, modulating processes such as apoptosis, angiogenesis, and cell cycle regulation.

At the same time, advances in phytochemistry, molecular biology, and biotechnology are enabling the identification, isolation, and modification of novel natural products with enhanced pharmacological activity and reduced toxicity. Secondary metabolites such as flavonoids, alkaloids, terpenoids, glucosinolates, and polyphenols exhibit promising chemopreventive and therapeutic properties, with many acting on molecular targets implicated in tumor initiation, progression, and metastasis. The integration of omics technologies, high-throughput screening, and synthetic biology is further accelerating the discovery pipeline for plant-derived anticancer agents.

With this in mind, we are pleased to invite you to contribute to the Special Issue of Molecules on “Effect of Natural Products in the Cancer Therapy Mechanism—2nd Edition“. This Issue will focus on the most recent advances in natural product–based cancer research.

We invite contributions in the form of original research articles, short communications, and reviews covering, among others, the following:

  • Plant-derived molecules with anticancer activity and their molecular targets;
  • Novel pharmacological models (in vitro and in vivo) for natural product testing;
  • Advances in isolation, structural characterization, and semisynthetic modification;
  • Biotechnological approaches to enhance production of bioactive metabolites;
  • Mechanistic insights into chemoprevention and therapy using natural compounds.

We warmly encourage you to share your latest findings and perspectives to advance the field of natural products in oncology and to inspire innovative therapeutic strategies.

Dr. Maciej Tarnowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer activities
  • therapeutic potential of plants
  • phytochemicals
  • natural products
  • apoptosis
  • metastasis
  • angiogenesis
  • molecular mechanisms
  • alkaloids
  • terpenoids
  • polyphenols

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 2065 KB  
Review
Plant-Derived Modulators of Tumor Metabolism as Novel, Efficacious, and Low-Toxicity Therapeutic Agents for Cancer Treatment
by Tania Mmapule Maphoso, Dakalo Portia Ramali, Thanyani Mulaudzi, Vinesh Maharaj, Cathryn Helena Stanford Driver and Botle Precious Damane
Molecules 2026, 31(9), 1394; https://doi.org/10.3390/molecules31091394 - 23 Apr 2026
Abstract
Metabolic reprogramming is a core hallmark of malignancy, enabling tumor cells to sustain rapid proliferation, evade immune elimination, and develop resistance to therapy. Although a wide range of plant-derived phytochemicals exhibit anticancer activity with comparatively low toxicity, their capacity to disrupt specific metabolic [...] Read more.
Metabolic reprogramming is a core hallmark of malignancy, enabling tumor cells to sustain rapid proliferation, evade immune elimination, and develop resistance to therapy. Although a wide range of plant-derived phytochemicals exhibit anticancer activity with comparatively low toxicity, their capacity to disrupt specific metabolic dependencies exploited by tumors has not been comprehensively synthesized. This review brings together current mechanistic evidence showing how major phytochemical classes, including polyphenols, terpenes and terpenoids, glucosinolates, and alkaloids, interfere with pathways central to tumor metabolic fitness, such as aerobic glycolysis, pentose phosphate pathway flux, mitochondrial substrate oxidation, glutamine dependence, and redox homeostasis. It further introduces a pathway-focused framework that links phytochemical mechanisms to quantifiable metabolic outcomes and highlights their potential to remodel the tumor microenvironment by altering nutrient competition, oxidative stress responses, and hypoxia-driven signaling. Key barriers such as poor systemic bioavailability, rapid metabolic degradation, and limited tissue penetration are assessed alongside emerging formulation and delivery strategies designed to enhance therapeutic exposure while preserving low-toxicity profiles. Mapping these mechanistic insights onto clinical development needs allows prioritization of specific phytochemical-metabolic pathway pairs with the strongest potential for translation. This positions plant-derived metabolic disruptors as promising candidates for next-generation, low-toxicity anticancer therapies that strategically exploit defined metabolic vulnerabilities. Full article
19 pages, 1183 KB  
Review
Natural Modulators of Aquaporins in Cancer Therapy: Functional Mechanisms and Clinical Potential
by Paulina Małkowska and Maciej Tarnowski
Molecules 2026, 31(7), 1072; https://doi.org/10.3390/molecules31071072 - 25 Mar 2026
Viewed by 495
Abstract
Aquaporins (AQPs) are increasingly recognized as key regulators of tumor progression, influencing key hallmarks of cancer progression and cellular homeostasis. Their frequent overexpression in malignancies highlights their potential as therapeutic targets, yet the development of selective synthetic inhibitors remains challenging due to structural [...] Read more.
Aquaporins (AQPs) are increasingly recognized as key regulators of tumor progression, influencing key hallmarks of cancer progression and cellular homeostasis. Their frequent overexpression in malignancies highlights their potential as therapeutic targets, yet the development of selective synthetic inhibitors remains challenging due to structural conservation and off-target toxicity. Natural compounds have recently emerged as promising modulators of AQP expression and function, offering greater molecular diversity and generally favorable safety profiles. This review synthesizes current evidence on phytochemicals, including bacopaside II, curcumin, resveratrol, quercetin, EGCG, all-trans retinoic acid, chrysin, and rottlerin, that interact with AQP isoforms relevant to cancer biology. These agents regulate AQPs through transcriptional control, redox modulation, signaling-pathway interference, or direct pore blockade, thereby attenuating oncogenic processes such as migration, angiogenesis, inflammation, and metabolic adaptation. Several compounds, notably bacopaside II and rottlerin, display isoform-selective inhibitory properties that directly impair AQP1- and AQP3-mediated permeability. Collectively, available evidence positions natural AQP modulators as promising lead compounds providing scaffolds for further drug development in oncology. Continued structural, mechanistic, and preclinical research is required to optimize isoform specificity and therapeutic efficacy, paving the way for their integration into future anticancer strategies. Full article
Show Figures

Figure 1

Back to TopTop